ENLIVEN THERAPEUTICS, INC.

Highlights Enliven Therapeutics, Inc.

Equities

ELVN

US29337E1029

Real-time Estimate Cboe BZX Other stock markets 10:38:19 2024-05-20 am EDT			5-day change	1st Jan Change
22.83 ^USD	-0.91%		-6.10%	+66.15%

May. 14	Enliven Therapeutics Q1 Loss Narrows	MT
Apr. 11	Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enliven Therapeutics Q1 Loss Narrows	May. 14	MT
Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	Apr. 11	CI
North American Morning Briefing : Investors -2-	Mar. 21	DJ
Enliven Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Enliven Therapeutics Q3 Loss Narrows	Nov. 09	MT
Enliven Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Enliven Therapeutics, Inc. completed the acquisition of IMARA Inc. from a group of shareholders for approximately $340 million in a reverse merger transaction.	23-02-22	CI
Enliven Therapeutics, Inc. entered into a definitive merger agreement to acquire IMARA Inc. from a group of shareholders in a reverse merger transaction.	22-10-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW